Campbell & CO Investment Adviser LLC trimmed its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 10.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 4,564 shares of the medical instruments supplier’s stock after selling 509 shares during the period. Becton Dickinson and makes up approximately 0.5% of Campbell & CO Investment Adviser LLC’s holdings, making the stock its 13th largest position. Campbell & CO Investment Adviser LLC’s holdings in Becton Dickinson and were worth $1,150,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Duality Advisers LP lifted its holdings in shares of Becton Dickinson and by 12.7% during the first quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock valued at $4,365,000 after purchasing an additional 1,970 shares during the last quarter. Meridian Wealth Advisors LLC lifted its holdings in shares of Becton Dickinson and by 2.7% during the first quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock valued at $946,000 after purchasing an additional 99 shares during the last quarter. Pratt Collard Advisory Partners LLC lifted its holdings in shares of Becton Dickinson and by 5.1% during the first quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock valued at $519,000 after purchasing an additional 100 shares during the last quarter. Investec Asset Management North America Inc. lifted its holdings in shares of Becton Dickinson and by 5.1% during the first quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock valued at $2,778,000 after purchasing an additional 543 shares during the last quarter. Finally, British Airways Pensions Investment Management Ltd lifted its holdings in shares of Becton Dickinson and by 10.3% during the first quarter. British Airways Pensions Investment Management Ltd now owns 87,805 shares of the medical instruments supplier’s stock valued at $21,928,000 after purchasing an additional 8,207 shares during the last quarter. Hedge funds and other institutional investors own 84.55% of the company’s stock.

NYSE BDX traded up $3.28 during mid-day trading on Tuesday, reaching $255.79. The stock had a trading volume of 609,473 shares, compared to its average volume of 1,218,157. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The firm has a market cap of $68.05 billion, a PE ratio of 23.23, a PEG ratio of 1.86 and a beta of 1.12. The business’s fifty day moving average price is $246.91. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same period in the previous year, the business earned $2.65 EPS. The firm’s revenue for the quarter was down .6% on a year-over-year basis. On average, research analysts expect that Becton Dickinson and Co will post 11.69 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.20%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of Becton Dickinson and stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total value of $687,836.82. Following the completion of the sale, the executive vice president now owns 9,408 shares of the company’s stock, valued at approximately $2,229,131.52. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Patrick Kaltenbach sold 191 shares of Becton Dickinson and stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $241.03, for a total transaction of $46,036.73. Following the completion of the sale, the executive vice president now directly owns 19,072 shares of the company’s stock, valued at approximately $4,596,924.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,154 shares of company stock valued at $4,955,775. 0.12% of the stock is currently owned by insiders.

A number of equities analysts recently weighed in on the stock. KeyCorp boosted their price objective on shares of Harsco from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, May 10th. Zacks Investment Research lowered shares of GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a report on Monday, May 20th. BMO Capital Markets boosted their price objective on shares of Sun Life Financial from C$58.00 to C$60.00 in a report on Friday, May 10th. Barclays lowered shares of Buckeye Partners from an “overweight” rating to an “equal weight” rating in a report on Monday, May 13th. Finally, Raymond James set a C$1.00 price objective on shares of Orezone Gold and gave the stock an “outperform” rating in a report on Friday, June 28th. Five equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $263.58.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Call Option Volume

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.